Systemic tolerance can be elicited by introducing antigen into an immune-privileged site, such as the eye, or directly into the blood. Both routes of immunization result in a selective deficiency of systemic delayed type hypersensitivity. Although the experimental animal model of anterior chamber–associated immune deviation (ACAID) occurs in most mouse strains, ACAID cannot be induced in several mutant mouse strains that are coincidentally deficient in natural killer T (NKT) cells. Therefore, this model for immune-privileged site–mediated tolerance provided us with an excellent format for studying the role of NKT cells in the development of tolerance. The following data show that CD1-reactive NKT cells are required for the development of systemic tolerance induced via the eye as follows: (a) CD1 knockout mice were unable to develop ACAID unless they were reconstituted with NKT cells together with CD1+ antigen-presenting cells; (b) specific antibody depletion of NKT cells in vivo abrogated the development of ACAID; and (c) anti-CD1 monoclonal antibody treatment of wild-type mice prevented ACAID development. Significantly, CD1-reactive NKT cells were not required for intravenously induced systemic tolerance, thereby establishing that different mechanisms mediate development of tolerance to antigens inoculated by these routes. A critical role for NKT cells in the development of systemic tolerance associated with an immune-privileged site suggests a mechanism involving NKT cells in self-tolerance and their defects in autoimmunity.
Skip Nav Destination
Article navigation
1 November 1999
Article|
November 01 1999
Cd1-Reactive Natural Killer T Cells Are Required for Development of Systemic Tolerance through an Immune-Privileged Site
Koh-Hei Sonoda,
Koh-Hei Sonoda
aSchepens Eye Research Institute, Harvard Medical School, Boston, Massachusetts 02114
Search for other works by this author on:
Mark Exley,
Mark Exley
bCancer Biology Program, Hematology/Oncology Division, Beth Israel-Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215
Search for other works by this author on:
Scott Snapper,
Scott Snapper
cGastrointestinal Unit (Medical Services) and Center for Study of Inflammatory Bowel Disease, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114
Search for other works by this author on:
Steven P. Balk,
Steven P. Balk
bCancer Biology Program, Hematology/Oncology Division, Beth Israel-Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215
Search for other works by this author on:
Joan Stein-Streilein
Joan Stein-Streilein
aSchepens Eye Research Institute, Harvard Medical School, Boston, Massachusetts 02114
dPulmonary and Critical Care Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115
Search for other works by this author on:
Koh-Hei Sonoda
aSchepens Eye Research Institute, Harvard Medical School, Boston, Massachusetts 02114
Mark Exley
bCancer Biology Program, Hematology/Oncology Division, Beth Israel-Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215
Scott Snapper
cGastrointestinal Unit (Medical Services) and Center for Study of Inflammatory Bowel Disease, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114
Steven P. Balk
bCancer Biology Program, Hematology/Oncology Division, Beth Israel-Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215
Joan Stein-Streilein
aSchepens Eye Research Institute, Harvard Medical School, Boston, Massachusetts 02114
dPulmonary and Critical Care Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115
Abbreviations used in this paper: ac, anterior chamber; ACAID, anterior chamber–associated immune deviation; B6, C57BL/6; DN, double negative; DTH, delayed type hypersensitivity; ES, embryonic stem; KO, knockout; LAT, local adoptive transfer; PEC, peritoneal exudate cell; RαAsGM1, rabbit antiasialo GM1; WT, wild-type.
Received:
May 04 1999
Revision Requested:
August 10 1999
Accepted:
August 23 1999
Online ISSN: 1540-9538
Print ISSN: 0022-1007
© 1999 The Rockefeller University Press
1999
The Rockefeller University Press
J Exp Med (1999) 190 (9): 1215–1226.
Article history
Received:
May 04 1999
Revision Requested:
August 10 1999
Accepted:
August 23 1999
Citation
Koh-Hei Sonoda, Mark Exley, Scott Snapper, Steven P. Balk, Joan Stein-Streilein; Cd1-Reactive Natural Killer T Cells Are Required for Development of Systemic Tolerance through an Immune-Privileged Site. J Exp Med 1 November 1999; 190 (9): 1215–1226. doi: https://doi.org/10.1084/jem.190.9.1215
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement